Resultats globals: 3 registres trobats en 0.01 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
13 p, 1.2 MB Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis / Diesch, Jeannine (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Le Pannérer, Marguerite Marie (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Winkler, René (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Casquero, Raquel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Muhar, Matthias (Research Institute of Molecular Pathology (IMP). Vienna BioCenter (VBC)) ; van der Garde, Mark (German Cancer Consortium (DKTK). Partner Site Munich) ; Maher, Michael (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Martínez Herráez, Carolina (Universitat de Barcelona. Departament de Bioquímica i Fisiologia) ; Bech-Serra, Joan-Josep (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Fellner, Michaela (Research Institute of Molecular Pathology (IMP). Vienna BioCenter (VBC)) ; Rathert, Philipp (University Stuttgart) ; Brooks, Nigel (CellCentric. Ltd. Chesterford Research Park) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Gentilella, Antonio (Universitat de Barcelona. Departament de Bioquímica i Fisiologia) ; De La Torre Gómez, Gisela Carolina (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zuber, Johannes (Medical University of Vienna. Vienna BioCenter (VBC)) ; Götze, Katharina S. (Technische Universität München) ; Buschbeck, Marcus (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
The nucleotide analogue azacitidine (AZA) is currently the best treatment option for patients with high-risk myelodysplastic syndromes (MDS). However, only half of treated patients respond and of these almost all eventually relapse. [...]
2021 - 10.1038/s41467-021-26258-z
Nature communications, Vol. 12 Núm. 1 (january 2021) , p. 6060  
2.
16 p, 4.4 MB Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes / Palau de Miguel, Anna (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Garz, Anne-Kathrin (German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany) ; Diesch, Jeannine (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zwick, Anabel (Technische Universität München) ; Malinverni, Roberto (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Valero, Vanesa (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Lappin, Katrina (Centre for Cancer Research and Cell Biology. Queen's University) ; Casquero, Raquel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Lennartsson, Andreas (Karolinska Institutet (Estocolm, Suècia). Department of Biosciences and Nutrition) ; Zuber, Johannes (Research Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna, Austria) ; Navarro, Tomàs (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Mills, Ken I. (Centre for Cancer Research and Cell Biology. Queen's University) ; Götze, Katharina S. (German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany) ; Buschbeck, Marcus (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
Genetic lesions affecting epigenetic regulators are frequent in myelodysplastic syndromes (MDS). Polycomb proteins are key epigenetic regulators of differentiation and stemness that act as two multimeric complexes termed polycomb repressive complexes 1 and 2, PRC1 and PRC2, respectively. [...]
2017 - 10.18632/oncotarget.22839
Oncotarget, Vol. 8 (december 2017) , p. 115002-115017  
3.
11 p, 577.8 KB A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers / Diesch, Jeannine (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zwick, Anabel (Technical University Munich. Department of Medicine) ; Garz, Anne-Kathrin (German Cancer Research Center (Heidelberg, Alemanya)) ; Palau de Miguel, Anna (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Buschbeck, Marcus (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Götze, Katharina S. (German Cancer Research Center (Heidelberg, Alemanya))
The azanucleosides azacitidine and decitabine are currently used for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in patients not only eligible for intensive chemotherapy but are also being explored in other hematologic and solid cancers. [...]
2016 - 10.1186/s13148-016-0237-y
Clinical epigenetics, Vol. 8 Núm. 71 (Juny 2016)  

Vegeu també: autors amb noms similars
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.